|
90% complete response for AKYNZEO (n=135) during the overall phase compared to 77% for oral palonosetron (n=136) (p=0.003)1
|
|
|
Indication
|
|
|
AKYNZEO is indicated for the prevention of acute and delayed nausea and vomiting associated with the initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. AKYNZEO is an oral fixed combination of palonosetron and netupitant: palonosetron prevents nausea and vomiting during the acute phase and netupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy.
|
|
|
Important Safety Information
|
|
|
Warnings and Precautions
|
|
| • |
Hypersensitivity reactions, including anaphylaxis, have been reported with or without known hypersensitivity to other 5‑HT3 receptor antagonists |
|
|
|
Please see below for additional Important Safety Information.
|
|
|
Exceptional power
|
|
|
AKYNZEO prevents 90% of CINV events over 5 days1
|
|
|
Complete response (no emesis and no use of rescue medication) for 5 days1
|
|
|
|
|
90% complete response demonstrated over 5 days with AKYNZEO compared to 77% for oral palonosetron1
|
|
|
Primary endpoint: complete response in overall phase (0‑120 hours)2
|
|
|
Complete response is defined as no emesis or use of rescue medications2
|
|
|
Study design in patients receiving high‑dose cisplatin1
|
|
|
Multicenter, randomized, double-blind, double-dummy, parallel-group study evaluating AKYNZEO (300 mg netupitant/0.5 mg palonosetron) vs oral palonosetron
|
|
|
Patients received cisplatin (≥50 mg/m2 either alone or in combination with other chemotherapy agents)2
|
|
| • |
Median cisplatin dose: 75 mg/m2 for each group |
|
|
|
Patients treated with AKYNZEO primarily had a diagnosis of lung/respiratory cancer (25.9%), head and neck cancer (24.4%), or ovarian cancer (17.8%)2
|
|
|
CINV=chemotherapy-induced nausea and vomiting.
|
|
|
|
|
Important Safety Information (continued)
|
|
|
Warnings and Precautions (continued)
|
|
| • |
Serotonin syndrome has been reported with 5‑HT3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs. Serotonin syndrome can be life threatening. Symptoms associated with serotonin syndrome may include the following combination of signs and symptoms: mental status changes, autonomic instability, neuromuscular symptoms, seizures, and gastrointestinal symptoms. Patients should be monitored for the emergence of serotonin syndrome, and if symptoms occur, discontinue AKYNZEO and initiate supportive treatment. Patients should be informed of the increased risk of serotonin syndrome, especially if AKYNZEO is used concomitantly with other serotonergic drugs
|
|
|
|
Adverse Reactions
|
|
| • |
Most common adverse reactions: headache, asthenia, dyspepsia, fatigue, constipation and erythema
|
|
|
|
Drug Interactions
|
|
| • |
Use with caution in patients receiving concomitant medications primarily metabolized by CYP3A4. The plasma concentrations of CYP3A4 substrates can increase when co‑administered with AKYNZEO. The inhibitory effect on CYP3A4 can last for multiple days
|
|
| |
- |
Dexamethasone doses should be reduced when given with AKYNZEO. A two-fold increase in the systemic exposure of dexamethasone was observed 4 days after single dose of netupitant
|
|
| |
- |
Consider the potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) when administering with AKYNZEO. When administered with netupitant, the systemic exposure to midazolam was significantly increased
|
|
| • |
Avoid concomitant use of AKYNZEO in patients on chronic use of a strong CYP3A4 inducer such as rifampin as this may decrease the efficacy of AKYNZEO
|
|
|
|
Use in Specific Populations
|
|
| • |
Avoid use of AKYNZEO in patients with severe hepatic impairment, severe renal impairment, or end-stage renal disease
|
|
|
|
For more information about AKYNZEO, please see Full Prescribing Information.
|
|
|
References: 1. AKYNZEO® (netupitant/palonosetron) capsules. Full Prescribing Information. 2. Hesketh P, Rossi G, Rizzi G, et al. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy‑induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose‑ranging pivotal study. Ann Oncol. 2014;25(7):1340-1346.
|
|
|
This is a post‑only mailing. Please do not reply to this email.
|
|
|
If you prefer not to receive further messages from this sender, please click here and confirm your request.
|
